Paracelsian AndroVir for AIDS, AndroCar for cancer, planned for 1997 launches.
This article was originally published in The Tan Sheet
Executive Summary
PARACELSIAN ANDROVIR, ANDROCAR SUPPLEMENTS PLANNED FOR LAUNCH next March and July, respectively. AndroVir (PN355) is a potential treatment for HIV and cancer; AndroCar (PN27,1) is for cancer. Ithaca, N.Y.-based Paracelsian expects to introduce the two products as dietary supplements bearing claims such as "For a healthier immune system" for AndroVir or "To support a person's well-being" for AndroCar. FDA has objected in the past to immune strengthening claims for dietary supplements, including Pacific Biologic's claims for Resist ("The Tan Sheet" July 29, p. 8).
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning